^
Association details:
| Biomarker: | MYC amplification |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Avastin (bevacizumab) (VEGF-A inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Multiple genetic variants predict the progression-free survival of bevacizumab plus chemotherapy in advanced ovarian cancer: A retrospective study
Published date:
09/03/2021
Excerpt:
Bevacizumab (BV)...Sixty two Chinese advanced OC patients treated with BV-based therapy were included. MYC Proto-Oncogene amplification seemed to have a positive trend (hazard ratio = 0.21, 95% CI 0.05-1.02, P = .052). EGFR or HER2 alterations are negative predictors of PFS for OC patient treated with BV plus chemotherapy.
DOI:
10.1097/MD.0000000000027130
